Bayer and Onyx have announced the initiation of a Phase III study of Nexavar (sorafenib) as an adjuvant therapy for patients with hepatocellular carcinoma
Filed under: kinase | Tagged: bayer, kinase, multikinase, Nexavar, onyx, phase iii, sorafenib